GLP-1 receptor agonists are among the most frequently denied medications in the United States, and most of those denials are one of two things: a prior authorization request that did not carry the documentation the plan's criteria ask for, or a benefit design that does not cover the drug for the reason it was prescribed. Those two look the same at the pharmacy counter and are answered very differently, so the first step is reading the denial closely enough to tell them apart.
Why was my GLP-1 denied?
Three reasons account for most of these denials.
Prior authorization criteria were not met on paper. Plans publish written criteria for this class, and they are detailed: a diagnosis, often a documented body mass index or a specific comorbidity, sometimes a period of documented lifestyle intervention, sometimes evidence that another agent was tried. A prescription sent without the chart notes that establish those points is denied on the record rather than on the medicine.
Step therapy. Many plans require a different agent first, whether an older drug in the same class or a different class entirely, before the prescribed one becomes available. If that is what happened, the denial is answered as a step therapy override rather than as a fresh authorization request.
The indication is not covered. A plan may cover semaglutide or tirzepatide for type 2 diabetes and exclude the weight-management versions of the same molecules, because weight-management drugs sit outside the pharmacy benefit on many contracts. This is a benefit design decision, not a clinical one, and it is the reason two people with the same prescription can get opposite answers from the same insurer.
What does the denial letter actually mean?
Denial notices for this class use a small vocabulary, and each phrase points somewhere different.
- "Prior authorization required" or "criteria not met": the drug is on the formulary and the request did not satisfy the published rule. This is the most appealable form, because the gap is documentary.
- "Non-formulary" or a tier that makes the drug unaffordable: the route is a formulary or tiering exception showing the covered alternatives are not appropriate for you.
- "Not a covered benefit" or "benefit exclusion": your contract excludes the category. Read this one carefully, because it is decided by the plan sponsor rather than by clinical review, and appeals go a different way.
- "Quantity limit exceeded": coverage exists but the dose or the days' supply requested falls outside the plan's limit, often during a titration schedule.
Your denial notice must state the specific reason and tell you how to appeal. If it does not name the criterion it applied, you can ask the plan in writing for the exact clinical criteria used, and that request is worth making the same day.
What can I do in the next 48 hours?
The general first steps after any denial are in our guide to the first 48 hours after a denial. For this class specifically, three things are worth doing early.
Find the appeal deadline on the notice, and note whether an expedited review is available. Ask your plan, in writing, for the criteria it applied and for a copy of its coverage policy for the drug. Then ask your prescriber's office for the chart notes that speak to those criteria: the diagnosis and how it was established, measurements and dates, comorbid conditions, and every previous medication tried for the same indication with dates, doses and what happened.
If you are not sure which kind of denial you are holding, the free denial check walks through five questions and returns the appeal path your letter points to. It takes about a minute and needs no account.
How does a physician-written appeal help for GLP-1 denials?
A denial in this class is answered by matching a written criterion to a written record, and that is clinical work. A licensed physician reads the records, decides whether the case has merit, and, where it does, writes a letter that names the plan's own criterion and shows where the chart satisfies it: the diagnosis and its basis, the measurements the policy asks for, the comorbid conditions, the prior therapies with their dates and outcomes, and the guideline and labeling support for the drug prescribed. Where a step requirement is at issue, the letter claims the specific exception ground the plan's policy provides instead of asking generally for reconsideration.
Cove Health cannot guarantee results, but you should not have to assemble that argument alone. If the case does not have merit, a physician tells you so before anything is written.
Cove Health provides advocacy services. Information on this site is general information, not legal or medical advice. Cove Health is not a law firm and does not provide legal representation, and submission of records does not guarantee a particular outcome.